SciVision Biotech Inc (1786) - Total Liabilities
Based on the latest financial reports, SciVision Biotech Inc (1786) has total liabilities worth NT$892.04 Million TWD (≈ $28.10 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of SciVision Biotech Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
SciVision Biotech Inc - Total Liabilities Trend (2009–2025)
This chart illustrates how SciVision Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SciVision Biotech Inc asset portfolio.
SciVision Biotech Inc Competitors by Total Liabilities
The table below lists competitors of SciVision Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Her Chee Industrial Co Ltd
TWO:8937
|
Taiwan | NT$1.93 Billion |
|
Red Star Macalline Group Corporation Ltd
F:3S5
|
Germany | €68.62 Billion |
|
I-Berhad
KLSE:4251
|
Malaysia | RM614.71 Million |
|
JEIO CO LTD (PROPOSED)
KQ:418550
|
Korea | ₩40.00 Billion |
|
Catur Sentosa Adiprana Tbk
JK:CSAP
|
Indonesia | Rp8.56 Trillion |
|
Kuen Ling Refrigerating Machinery Co Ltd
TWO:4527
|
Taiwan | NT$1.27 Billion |
|
Aurora World Corporation
KQ:039830
|
Korea | ₩425.37 Billion |
|
Cellectis
PA:ALCLS
|
France | €229.03 Million |
Liability Composition Analysis (2009–2025)
This chart breaks down SciVision Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SciVision Biotech Inc net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SciVision Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SciVision Biotech Inc (2009–2025)
The table below shows the annual total liabilities of SciVision Biotech Inc from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$689.35 Million ≈ $21.72 Million |
+50.70% |
| 2024-12-31 | NT$457.43 Million ≈ $14.41 Million |
-14.29% |
| 2023-12-31 | NT$533.66 Million ≈ $16.81 Million |
-9.13% |
| 2022-12-31 | NT$587.30 Million ≈ $18.50 Million |
-27.68% |
| 2021-12-31 | NT$812.06 Million ≈ $25.58 Million |
+66.90% |
| 2020-12-31 | NT$486.55 Million ≈ $15.33 Million |
-2.90% |
| 2019-12-31 | NT$501.08 Million ≈ $15.79 Million |
-18.88% |
| 2018-12-31 | NT$617.70 Million ≈ $19.46 Million |
-4.78% |
| 2017-12-31 | NT$648.72 Million ≈ $20.44 Million |
+40.13% |
| 2016-12-31 | NT$462.93 Million ≈ $14.58 Million |
+272.86% |
| 2015-12-31 | NT$124.16 Million ≈ $3.91 Million |
+80.43% |
| 2014-12-31 | NT$68.81 Million ≈ $2.17 Million |
+52.13% |
| 2013-12-31 | NT$45.23 Million ≈ $1.43 Million |
-21.07% |
| 2012-12-31 | NT$57.31 Million ≈ $1.81 Million |
+42.67% |
| 2011-12-31 | NT$40.17 Million ≈ $1.27 Million |
-63.89% |
| 2010-12-31 | NT$111.24 Million ≈ $3.50 Million |
+6.64% |
| 2009-12-31 | NT$104.31 Million ≈ $3.29 Million |
-- |
About SciVision Biotech Inc
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was fo… Read more